Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Molecular Partners Annoucnced ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19 Did Not Pass Futility Criteria; Share Price Down 37% Premarket

Molecular Partners AG (NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that a planned futility analysis of ensovibep in the ongoing ACTIV-3 clinical study (NCT04501978) has not met the thresholds required to continue enrollment o

MOLN